Nuocheng Jianhua held the first investor R&D day

Dr.
Ruiqin Liu, Vice President of Biology and Business Management, Nuocheng Jianhua

"'Science-driven innovation' is the core concept we always adhere to, so we will continue to increase the source of innovation investment, balance the differentiated layout, and build a sustainable development pipeline
.
"

Dr.
Ouyang Xuesong, Vice President of Biology, Nuocheng Jianhua

"Nuocheng Jianhua will introduce large-molecule projects in the clinical stage, and through the integration with abutinib and other small-molecule projects of its own, to quickly maximize market value
.
We will also focus on tumor immunity, especially safe and effective Cytokines and immunosuppression of tumors are relieved, and cooperation in the development of early preclinical macromolecular projects
.
In addition, the company will also establish its own comprehensive macromolecular drug research and development platform to achieve a balanced pipeline of biological drug discovery, development and production
.
"

Dr.
Chen Xiangyang, Chief Technology Officer of Nuocheng Jianhua

"Nuocheng Jianhua has built a'one-stop' R&D platform and an efficient new drug development process
.
Our scientists design drugs based on protein structure, develop new drug molecules with different mechanisms of action, and develop more and better new drugs.
To the clinic
.
We are also actively trying to use new technologies such as artificial intelligence for research and development to accelerate the progress of research and development
.
"

Dr.
Zhichao Si, Senior Director of Marketing and Medical Affairs, Nuocheng Jianhua

“Nuocheng Jianhua’s commercialization team and R&D department have built a good two-way communication mechanism
.
We are not only committed to bringing innovative drugs from the source to benefit more patients in need as quickly as possible, and ensuring that the results of drug R&D are maximized to meet clinical needs.
At the same time, we also feed back market demand to the R&D team in a timely manner, so as to achieve the same frequency interaction between drug R&D and commercialization, and truly realize the concept
of “ science-driven innovation, patient needs-oriented ”.
"